M
MAIA Biotechnology, Inc.
MAIACIK 0001878313NYSEEmerging GrowthPharmaceutical PreparationsDelawareFY ends Dec 31
Period
FY 2025
Revenue
—
Net Income
$-22.40M
Total Assets
$9.70M
Equity
$2.38M
Shares Out
60.80M
Op. Cash Flow
$-18.84M
Business
MAIA Biotechnology, Inc. is a clinical-stage biopharmaceutical company developing targeted immunotherapies that leverage telomere-targeting to induce cancer-specific immune responses. Its main product candidate is THIO (6-thio-2'-deoxyguanosine, also called ateganosine), a small-molecule telomere-targeting agent in Phase 2/3 clinical development, plus a discovery pipeline of second‑generation telomere-targeting compounds. Key business activities include clinical development, preclinical research and discovery, and licensing/collaboration arrangements for checkpoint inhibitor combinations. The company conducts and sponsors trials across the United States, Europe, Australia and selected Asian markets through partnerships and clinical trial networks.
Summary from filing dated 2025-03-21
Financials
Consolidated Statement of Income
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Research and development expenses | 15 | 10 | — | — | — | |
| General and administrative expenses | 10 | 7 | 9 | 6 | 4 | |
| Total operating expenses | 24 | 17 | 20 | 16 | 8 | |
| Loss from operations | −24 | −17 | −20 | −16 | −8 | |
| Interest expense | — | −57 | — | — | — | |
| Interest income | 313,954 | 318,367 | — | — | — | |
| Australian research and development incentives | — | 79,954 | 176,719 | 313,625 | 43,666 | |
| Grant income | 361,350 | — | — | — | — | |
| Change in fair value of warrant liability | 1 | −7 | 205,130 | 98,394 | −2 | |
| Loss on fair value of warrants over proceeds | — | −12,952 | — | — | — | |
| Other income (expense) net: | 2 | −6 | 409,476 | 406,922 | −5 | |
| Net loss | −22 | −23 | — | — | — | |
| Net loss per share - basic | −0.7 | −1.05 | −1.49 | −1.75 | −2.37 | |
| Net loss per share - diluted | −0.7 | −1.05 | −1.49 | −1.75 | −2.37 | |
| Weighted average common shares outstanding - basic | 32 | 22 | 13 | 9 | 5 | |
| Weighted average common shares outstanding - diluted | 32 | 22 | 13 | 9 | 5 |
Consolidated Balance Sheet
As of · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash | 9 | 10 | 7 | 11 | 11 | |
| Prepaid expenses and other current assets | 1 | 473,834 | 268,677 | 554,321 | 54,537 | |
| Australia research and development incentives receivable | — | 77,347 | 144,680 | 302,789 | 43,666 | |
| Total current assets | 10 | 10 | 8 | 12 | 11 | |
| Other assets | 2,800 | 2,800 | 2,800 | 2,800 | 3,122 | |
| Total assets | 10 | 10 | 8 | 12 | 11 | |
| Accounts payable | 2 | 2 | 2 | 1 | 960,401 | |
| Accrued expenses | 4 | 2 | 3 | 2 | 1 | |
| Total current liabilities | 6 | 4 | 5 | 3 | 2 | |
| Warrant liability | 1 | 3 | — | — | — | |
| Total liabilities | 7 | 7 | 7 | 4 | 2 | |
| Commitments and contingencies (Note 7) | — | — | — | — | — | |
| Preferred stock, 0.0001 par value, 30,000,000 shares authorized at December 31, 2025 and December 31, 2024, 0 shares issued and outstanding | — | — | — | — | — | |
| Common stock, $0.0001 par value, 150,000,000 and 70,000,000 shares authorized at December 31, 2025 and December 31, 2024, 38,624,289 and 26,157,788 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively | 3,863 | 2,616 | 1,699 | 1,096 | 758 | |
| Additional paid-in capital | 112 | 91 | 64 | 53 | 38 | |
| Accumulated deficit | −110 | −87 | −64 | −44 | −28 | |
| Accumulated other comprehensive loss | −50,228 | −30,615 | −16,260 | −15,973 | — | |
| Total stockholders equity | 2 | 4 | 477,511 | — | — | |
| Total liabilities and stockholders equity | 10 | 10 | 8 | 12 | 11 |
Consolidated Statement of Cash Flows
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Stock-based compensation | 3 | 2 | 3 | 2 | 3 | |
| Restricted shares issued for consulting and research expense | 618,813 | 179,490 | — | — | — | |
| Prepaid expenses and other current assets | −579,766 | −195,935 | 285,831 | −505,233 | −15,155 | |
| Australia research and development incentives receivable | 80,410 | 56,805 | 158,405 | — | — | |
| Accounts payable | 519,720 | −118,827 | 471,897 | 211,346 | 805,516 | |
| Accrued expenses | 1 | −979,792 | 2 | 915,742 | 997,126 | |
| Net cash used in operating activities | −19 | −16 | −13 | −12 | −4 | |
| Proceeds from exercise of stock options | 844 | 217,158 | 1,432 | 84,000 | 9,000 | |
| Proceeds from exercise of warrants | 901,578 | — | — | 385,400 | 529,425 | |
| Proceeds from At-The-Market offering | 7 | 10 | — | 12 | — | |
| Payment of offering transactions costs | −617,133 | −795,257 | −2 | — | — | |
| Net cash provided by financing activities | 18 | 18 | 9 | 12 | 14 | |
| Net effect of foreign currency exchange on cash | −5,216 | −21,545 | −117 | −4,430 | — | |
| Net (decrease) increase in cash | −943,267 | 2 | — | — | — | |
| Warrants issued in connection with private placement offering 1 2024 | — | 2 | — | — | — | |
| Warrants issued in connection with private placement offering 2 2024 | — | 1 | — | — | — | |
| Warrants issued in connection with private placement offering 3 2024 | — | 677,919 | — | — | — | |
| Warrants issued in connection with private placement offering 4 2024 | — | 2 | — | — | — | |
| Warrants issued in connection with private placement offering 5 2024 | — | 635,345 | — | — | — | |
| Warrants issued in connection with private placement offering 1 2025 | 1 | — | — | — | — | |
| Warrants issued in connection with private placement offering 2 2025 | 571,566 | — | — | — | — | |
| Warrants issued in connection with private placement offering 3 2025 | 462,592 | — | — | — | — | |
| Warrants issued in connection with private placement offering 4 2025 | 300,245 | — | — | — | — | |
| Warrants issued in connection with private placement offering 5 2025 | 865,348 | — | — | — | — | |
| Warrants issued in connection with private placement offering 6 2025 | 251,539 | — | — | — | — | |
| Warrants issued in connection with private placement offering 7 2025 | 546,723 | — | — | — | — |
Filings
Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro
Material Events
Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro
Insiders
Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro
Institutional Holders
Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro
Frequently asked questions
What is MAIA Biotechnology, Inc.'s CIK number?
MAIA Biotechnology, Inc.'s SEC CIK number is 0001878313 (1878313). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find MAIA Biotechnology, Inc.'s SEC filings?
All of MAIA Biotechnology, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.